Safety and Effectiveness of Nimotuzumab in the Treatment of Advanced Head and Neck Cancer Patients. Phase IV Clinical Trial: Final Results
Published on: 2019-03-12
Objective: Epidermal Growth Factor Receptor (EGFR) can be overexpressed in head and neck cancer (HNC). Nimotuzumab is a humanized monoclonal antibody (hMab) that binds to the EGFR. A phase IV study was conducted in advanced head and neck newly diagnosed and recurrent cancer patients to evaluate safety and efficacy of nimotuzumab.